`
`
`
`Sean R. Kelly
`(973) 622-4801
`skelly@saiber.com
`
`
`
`
`
`
`
`
`
`
`
`August 5, 2014
`
`
`
`
`
`
`
`
`
`VIA ELECTRONIC FILING AND FIRST CLASS MAIL
`The Honorable Esther Salas, U.S.D.J.
`United States District Court
`Martin Luther King Jr. Federal Courthouse
`50 Walnut Street, Room 2060
`Newark, New Jersey 07101
`
`Re:
`
`
`Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC
`C.A. No. 13-cv-391
`
`
`
`
`
`Dear Judge Salas,
`
`
`
`This firm, together with Arent Fox LLP, represents Defendant Par Pharmaceutical, Inc.
`(“Par”) in the above-captioned consolidated matter. We write today to inform you that Par and
`Roxane Laboratories, Inc. have filed a petition for Covered Business Method Patent review of
`one of the patents at issue in this Action, U.S. Patent No. 7,765,106 (“the ’106 patent”) under 35
`U.S.C. § 321 and § 18 of the Leahy-Smith America Invents Act (“Petition”) in the United States
`Patent and Trademark Office (“USPTO”) on August 4, 2014. The Petition is assigned Trial No.
`CBM2014-00161.
`
`
`
`The Petition seeks for the USPTO to admit the ’106 patent to Covered Business Method
`Patent Review and, subsequently, to cancel all claims of the ’106 patent on multiple grounds. As
`the outcome of the Petition could result in the cancellation of one or more claims of the ’106
`patent and affect Jazz Pharmaceuticals, Inc.’s ability to assert infringement of those claims in this
`case, we wanted to inform Your Honor of the concurrent proceedings before the USPTO.
`
`
`
`The USPTO has discretion over whether to grant the Petition and admit the ’106 patent to
`Covered Business Method Patent review and has not yet done so. Accordingly, no action is
`required or sought from Your Honor at this time.
`
`Respectfully submitted,
`
`s/ Sean R. Kelly
`Sean R. Kelly
`
`
`
`
`
` cc: All counsel of record (by CM/ECF)
`
`
`
`
`
`